RB nr 17/2008

Legal basis: § 5 subpar. 1 pt. 1 of RO and § 7 of RO

The Management Board of MCI Management S.A. informs that on March 5, 2008 MCI.BioVentures Sp. z o.o. – a subsidiary of MCI Management SA acquired 450 new shares of the nominal value of PLN 50.00 each in DNA Serwis sp. z o.o. (currently in the process of changing its name to Genomed Sp. z o.o.) MCI.BioVentures paid PLN 900 thousand in cash for the purchased shares that is PLN 2 thousand per each share. As a result of the transaction of purchase of the new shares MCI.BioVentures holds 31.03% in the share capital of DNA Serwis Sp. z o.o.

The transaction was made in the wake of the fulfillment of the terms and conditions of the investment agreement concluded between MCI.BioVentures and DNA Serwis on January 23, 2008 and constitutes the first round of financing.

DNA Serwis Sp. z o.o. offers such services as analysis of DNA sequences used in medical molecular diagnostics, industry, science and forensic medicine. Sequencing DNA is one of the basic methods in molecular biology applied both commercially and in research centers as well as in medicine in early detection of some genetically-related diseases.

MCI.BioVentures is a seed capital fund investing up to EUR 1 million in companies operating in the sectors of biotechnology, new drugs and healthcare in Poland. The fund’s means will be spent on investments in companies at their early stage of growth (seed and start-up). Expected volume of MCI.BioVentures shall reach PLN 20 million. 50% of the capital will come from additional funds which MCI.BioVentures raised on the basis of an agreement with the Polish Agency for Enterprise Development.

This is a long-term investment. There are no connections referred to in § 7 subpar 6 of RO. The purchased assets represent over 20% of the share capital of DNA Serwis Sp. z o.o. and they are considered assets of significant value.